US Drug Patent 6,703,396: Emtricitabine Claims, Patent Scope, Expiration, and Generic Entry Risk

US Patent 6,703,396 covers the substantially pure negative enantiomer of emtricitabine, also known as FTC, including specified salts, esters, phosphate derivatives, pharmaceutical compositions, and administration forms. The patent issued on March 9, 2004, and its ordinary US patent term has expired. The claims were directed principally to the active pharmaceutical ingredient rather than to a later-developed tablet formulation or combination product.

The patent was commercially important because emtricitabine became the nucleoside reverse transcriptase inhibitor component of Emtriva, Truvada, Atripla, Complera/Eviplera, Stribild, and other antiretroviral products. The patent itself no longer presents a blocking US exclusivity right.

What drug does US Patent 6,703,396 protect?

US 6,703,396 protects the negative, or (-), enantiomer of cis-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolane-5-yl)-(1H)-pyrimidin-2-one. This compound is emtricitabine.

Emtricitabine is a cytidine nucleoside analog and HIV nucleoside reverse transcriptase inhibitor. Its commercial products include:

Product	Active ingredients	FDA product type
Emtriva	Emtricitabine	Single-ingredient antiretroviral
Truvada	Emtricitabine and tenofovir disoproxil fumarate	Fixed-dose combination
Atripla	Efavirenz, emtricitabine, and tenofovir disoproxil fumarate	Fixed-dose combination
Complera/Eviplera	Rilpivirine, emtricitabine, and tenofovir disoproxil fumarate	Fixed-dose combination
Stribild	Elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate	Fixed-dose combination

The compound is also used in Descovy, although Descovy contains tenofovir alafenamide rather than tenofovir disoproxil fumarate.

What are the principal claims of US 6,703,396?

The claims fall into five technical groups.

Enantiomerically pure emtricitabine

Claims 1 through 5 cover the (-)-enantiomer with limits on the amount of the corresponding (+)-enantiomer:

Claim group	Main limitation
Claim 1	(-)-enantiomer at least 95% free of the (+)-enantiomer
Claim 2	The (-)-enantiomer, including pharmaceutically acceptable salts and esters
Claim 3	Substantially pure (-)-enantiomer with no more than 5% w/w (+)-enantiomer
Claim 4	No more than about 2% w/w (+)-enantiomer
Claim 5	Less than 1% (+)-enantiomer

The claims establish purity thresholds as claim limitations. A product containing more than 5% of the corresponding (+)-enantiomer would not satisfy claims 1 or 3 through 5 as written, although other claims and other patent families would need separate analysis.

Salts and ester forms

Claims 2, 7, and 12 cover pharmaceutically acceptable salts, esters, and salts of esters. Claim 12 specifically requires a pharmaceutically acceptable salt of the substantially enantiopure compound.

This language is important because a generic applicant could not avoid the compound claims merely by selecting a conventional pharmaceutically acceptable salt if the salt remains within the claim construction.

5'-O derivatives and phosphate forms

Claims 8 through 11 cover chemical derivatives:

5'-O-alkyl derivatives;
5'-O-alkyl carbonyl derivatives;
Acetyl, propionyl, butyryl, and pentanoyl derivatives; and
Mono-, di-, and triphosphate forms.

These claims reach beyond the parent nucleoside. They could cover prodrug or intracellularly relevant derivative structures, subject to claim construction, written-description support, enablement, and infringement analysis.

Pharmaceutical compositions

Claim 6 covers a pharmaceutical composition containing a compound of claims 2 through 5 with a pharmaceutically acceptable carrier.

Claims 13 and 14 add an “effective HIV treatment amount for humans” and cover compositions containing the enantiopure compound or a pharmaceutically acceptable salt.

Administration routes and dosage forms

Claims 15 through 28 address:

Oral administration;
Tablets;
Capsules;
Liquid formulations;
Intravenous administration;
Sterile injectable diluents; and
Topical administration.

These claims are narrower than the active-compound claims. A commercial product that falls outside a particular dosage-form or route limitation could still implicate the broader compound or composition claims.

How broad is the patent’s legal scope?

The strongest part of the patent estate was the direct coverage of substantially pure (-)-emtricitabine. Claims 1 through 5 and 12 are composition-of-matter claims with purity limitations. They do not require a particular tablet excipient, dosage strength, indication, or branded product.

A product containing emtricitabine at pharmaceutical purity would historically have faced substantial infringement risk if the compound met the claimed enantiomeric-purity threshold. The claims also reach pharmaceutically acceptable salts and certain ester forms.

The composition and administration claims are narrower. They require a pharmaceutical composition, a carrier or diluent, and in some instances a particular administration route. They would have been less effective against a generic product that did not meet a specified route or dosage-form limitation, but the compound claims could independently create infringement exposure.

The patent does not expressly claim:

A specific emtricitabine tablet strength;
A particular excipient system;
A particular fixed-dose combination with tenofovir;
A specific manufacturing process;
A treatment regimen defined by dosing frequency;
HIV pre-exposure prophylaxis; or
A particular crystalline or polymorphic form.

Those subjects may be covered, if at all, by separate patents or regulatory exclusivities.

When did US Patent 6,703,396 expire?

US 6,703,396 expired in December 2015 under its ordinary patent term, based on the patent-family priority and US patent-term rules. The patent is therefore no longer an enforceable US patent blocking commercial manufacture or sale of emtricitabine.

Event	Date
Earliest relevant priority period	1990s
US patent issuance	March 9, 2004
Ordinary US patent-term endpoint	December 2015
Current status	Expired

The issue date did not determine the expiration date. For post-June 8, 1995 US applications, patent term generally runs 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment, terminal disclaimers, patent-term extension, and other statutory rules. The relevant family term, rather than the 2004 issue date, controlled.

No currently enforceable US exclusivity should be attributed to US 6,703,396.

What is the Orange Book status of emtricitabine?

Emtricitabine is approved under FDA New Drug Application 021500 for Emtriva. The FDA Orange Book historically listed patents associated with emtricitabine-containing products, including patents directed to emtricitabine and combination-product protection.

The Orange Book distinguishes between:

Drug-substance patents;
Drug-product patents;
Method-of-use patents; and
Patents listed against a particular NDA.

US 6,703,396 was a drug-substance and composition patent rather than a narrow tablet-formulation patent. Its expiration removed the patent from the category of live US barriers to ANDA approval or launch.

FDA approval of a generic emtricitabine product requires the applicant to establish pharmaceutical equivalence and bioequivalence under the ANDA pathway. Because emtricitabine is a small molecule, biosimilar procedures do not apply.

Were Paragraph IV challenges relevant?

Paragraph IV certifications historically would have been the principal mechanism for challenging listed, unexpired emtricitabine patents in an ANDA.

A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or will not be infringed. Filing a Paragraph IV certification can trigger patent litigation under the Hatch-Waxman Act and may create a 30-month stay of FDA approval, subject to statutory conditions.

For US 6,703,396, any Paragraph IV dispute became commercially significant before the patent’s December 2015 expiration. After expiration, the patent could no longer support a conventional Hatch-Waxman launch injunction. A later ANDA applicant could still have faced other unexpired patents listed for a specific product, but not an enforceable barrier from this patent alone.

Which companies challenged or commercialized emtricitabine?

The commercial rights originated with the academic and biotechnology inventors associated with Emory University and Triangle Pharmaceuticals. Gilead Sciences acquired Triangle Pharmaceuticals in 2003 and obtained the relevant emtricitabine commercial rights.

Company or institution	Role
Emory University and associated inventors	Origin of key nucleoside research and patent rights
Triangle Pharmaceuticals	Early commercial developer of emtricitabine
Gilead Sciences	Acquirer of Triangle and subsequent commercial sponsor
Generic manufacturers	ANDA applicants after relevant patent barriers expired

Public reporting did not consistently disclose standalone Emtriva revenue separately from broader Gilead HIV product revenue. The commercial exposure from emtricitabine was therefore concentrated in combination products, especially Truvada and Atripla, rather than measurable solely through Emtriva sales.

What other patents were relevant to emtricitabine?

US 6,703,396 was part of a broader emtricitabine and oxathiolane-nucleoside patent landscape. Related patent families included earlier compound patents and additional patents directed to enantiomerically pure nucleosides, processes, formulations, and combination products.

A high-level landscape is:

Patent category	Typical subject matter	Relevance
Early nucleoside patents	Oxathiolane nucleoside structures and antiviral activity	Foundational compound coverage
Enantiomer patents	Substantially pure (-)-emtricitabine	Direct protection of the commercial API
Process patents	Resolution, synthesis, purification, and intermediates	Manufacturing barriers
Formulation patents	Tablets, excipients, stability, and dosage forms	Product-specific protection
Combination patents	Emtricitabine with tenofovir or other antiretrovirals	Product and regimen protection
Method-of-use patents	HIV treatment, prevention, or dosing uses	Indication-specific protection

US 5,814,639 and US 6,642,245 are commonly identified as related or adjacent patents in the emtricitabine landscape. Their precise scope and expiration dates must be assessed separately from US 6,703,396 because continuation, divisional, terminal-disclaimer, and patent-term-adjustment rules can produce different claim sets and term calculations.

Did US 6,703,396 protect Truvada?

The patent could cover the emtricitabine component of a Truvada tablet if the tablet contained the claimed enantiomer and satisfied the relevant composition limitations. It did not, by itself, provide complete patent coverage for the entire fixed-dose combination.

Truvada contains:

Emtricitabine; and
Tenofovir disoproxil fumarate.

A Truvada product could therefore implicate separate patents directed to tenofovir disoproxil fumarate, the combination, the tablet formulation, or manufacturing methods. US 6,703,396 should not be treated as the sole patent governing Truvada market entry.

What generic entry risks existed?

Before expiration, the principal generic risks were:

Direct API infringement. A generic emtricitabine product meeting the claimed purity threshold could fall within claims 1 through 5.
Salt and derivative coverage. Selecting a salt or covered ester would not necessarily avoid claims 2, 7, or 12.
Composition infringement. Tablets, capsules, liquids, and injectable compositions could implicate claims 6 and 13 through 28.
Combination-product exposure. Truvada and other combinations could face separate patent barriers.
Manufacturing-process exposure. A noninfringing product composition could still raise process-patent issues if the generic used a protected synthesis or purification route.
Regulatory timing. FDA approval could be delayed by other listed patents even after US 6,703,396 expired.

The commercial launch analysis therefore required a patent-by-patent review of the relevant NDA, not reliance on this patent alone.

How strong was the patent estate?

At its peak, the patent had strong exclusionary characteristics because it claimed the marketed enantiomer as a pharmaceutical substance and included explicit purity thresholds. A competitor could not avoid the core claims simply by changing tablet shape, excipients, or packaging.

The estate was weaker in four respects:

The core patent was limited to the identified enantiomer and specified derivative forms.
The purity limitations created factual infringement questions where an accused product contained measurable levels of the opposite enantiomer.
The administration-route claims were narrower than the compound claims.
The patent term expired in 2015, eliminating current US enforcement value.

The patent’s historical strength was high. Its current blocking value is zero because the patent has expired.

Key Takeaways

US 6,703,396 covers substantially pure (-)-emtricitabine, the active ingredient in Emtriva.
Claims 1 through 5 and 12 are the core API and salt claims.
Claims 8 through 11 cover selected 5'-O derivatives and phosphate forms.
Claims 6 and 13 through 28 cover pharmaceutical compositions, dosage forms, and administration routes.
The patent expired in December 2015.
It is not a current US exclusivity barrier to generic emtricitabine.
Generic applicants use the ANDA pathway, not a biosimilar pathway.
Separate patents may have affected Truvada, Atripla, Complera/Eviplera, Stribild, and other combination products.
Historical Paragraph IV litigation risk was significant before expiration, but US 6,703,396 cannot now support a patent-based launch injunction.
The commercial value of emtricitabine was concentrated in Gilead’s combination HIV products.

FAQs About US Patent 6,703,396 and Emtricitabine

Is US Patent 6,703,396 still enforceable?

No. The patent expired in December 2015 and no longer provides enforceable US patent rights.

Does the patent cover racemic emtricitabine?

The claims are directed to the (-)-enantiomer and specified levels of the corresponding (+)-enantiomer. A racemic mixture would not ordinarily satisfy the claimed enantiomeric-purity limitations.

Does changing emtricitabine into a salt avoid the patent?

Not necessarily. Claims 2, 7, and 12 expressly include pharmaceutically acceptable salts, and claim 12 retains the enantiomeric-purity requirement.

Is emtricitabine subject to biosimilar competition?

No. Emtricitabine is a chemically synthesized small molecule. Generic manufacturers use the ANDA pathway rather than the biologics license application or biosimilar pathway.

Can a generic company launch an emtricitabine product after this patent expired?

Yes, subject to FDA approval and any remaining enforceable patents or regulatory exclusivities associated with the specific product or combination. US 6,703,396 alone does not prevent launch.

References

United States Patent and Trademark Office. (2004). US Patent No. 6,703,396: Enantiomerically pure cis nucleoside analogues.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
U.S. Food and Drug Administration. (2003). Emtriva (emtricitabine) prescribing information.
U.S. Food and Drug Administration. (2004). Truvada prescribing information.
Gilead Sciences, Inc. (2003). Annual report.
United States Patent and Trademark Office. (1999). US Patent No. 5,814,639.
United States Patent and Trademark Office. (2003). US Patent No. 6,642,245.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	9104741	Mar 06, 1991
United Kingdom	9109505	May 02, 1991

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	0513200	⤷ Start Trial	91073	Luxembourg	⤷ Start Trial
European Patent Office	0513200	⤷ Start Trial	300148	Netherlands	⤷ Start Trial
European Patent Office	0513200	⤷ Start Trial	SPC/GB04/016	United Kingdom	⤷ Start Trial
European Patent Office	0513200	⤷ Start Trial	SZ 7/2004	Austria	⤷ Start Trial
European Patent Office	0513200	⤷ Start Trial	C00513200/01	Switzerland	⤷ Start Trial
European Patent Office	0513200	⤷ Start Trial	7/2004	Austria	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 6,703,396

Summary for Patent: 6,703,396